-

nihao guest [ sign in / register ]
2018-9-25 2:27:39


Lapuente D, Ruzsics Z, Thirion C, Tenbusch M, et a. Evaluation of adenovirus 19a as a novel vector for mucosal vaccination against influenza A viruses. Lapuente D, Ruzsics Z, Thirion C, Tenbusch M, et a
submited by kickingbird at Apr, 16, 2018 9:8 AM from Lapuente D, Ruzsics Z, Thirion C, Tenbusch M, et a

Since preexisting immunity and enhanced infection rates in a clinical trial of an HIV vaccine have raised some concerns on adenovirus (Ad) serotype 5-based vaccines, we evaluated the subgroup D adenovirus serotype Ad19a for its suitability as novel viral vector vaccine against mucosal infections. In BALB/c mice, we compared the immunogenicity and efficacy of E1/E3-deleted Ad19a vectors encoding the influenza A virus (IAV)-derived antigens hemagglutinin (HA) and nucleoprotein (NP) to the most commonly used Ad5 vectors. The adenoviral vectors were applied intranasally and induced detectable antigen-specific T cell responses in the lung and in the spleen as well as robust antibody responses. A prior DNA immunization significantly improved the immunogenicity of both vectors and resulted in full protection against a lethal infection with a heterologous H3N2 virus. Nevertheless, the Ad5-based vectors were slightly superior in reducing viral replication in the lung which corresponded to higher NP-specific T cell responses measured in the lungs.

See Also:

Latest articles in those days:

[Go Top]    [Close Window]

Related Pages:
Learn about the flu news, articles, events and more
Subscribe to the weekly F.I.C newsletter!


  

Site map  |   Contact us  |  Term of use  |  FAQs
Copyright ©www.flu.org.cn. 2004-2018. All Rights Reserved. Powered by FIC 4.0.1
  Email:webmaster@flu.org.cn